Trade Ultragenyx Pharmaceutical Inc - RARE CFD

Add to favourite

33.79

6.61%

0.13

Low: 33.66

High: 35.55

Market Trading Hours* (UTC) Opens on Wednesday at 13:30

Mon - Fri: 13:30 - 20:00

Summary
Historical Data

Trading сonditions

Spread

0.13

Long position overnight fee

-0.023679%

Short position overnight fee

0.001457%

Overnight fee time

21:00 (UTC)

Min traded quantity

Currency

USD

Margin

50.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	36.18
Open	35.01
1-Year Change	-24.94%
Day's Range	33.66 - 35.55

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Mar 31, 2025	36.18	-0.67	-1.82%	36.85	36.86	35.50
Mar 28, 2025	37.75	-0.55	-1.44%	38.30	38.53	37.63
Mar 27, 2025	38.84	1.42	3.79%	37.42	39.07	37.42
Mar 26, 2025	37.93	-0.18	-0.47%	38.11	38.61	36.64
Mar 25, 2025	38.65	-0.25	-0.64%	38.90	38.90	38.05
Mar 24, 2025	39.31	0.13	0.33%	39.18	39.73	38.89
Mar 21, 2025	39.12	0.59	1.53%	38.53	39.16	37.86
Mar 20, 2025	38.84	0.03	0.08%	38.81	40.02	38.81
Mar 19, 2025	39.63	0.98	2.54%	38.65	40.07	38.45
Mar 18, 2025	38.81	-0.15	-0.39%	38.96	39.15	38.17
Mar 17, 2025	39.57	0.91	2.35%	38.66	40.00	38.42
Mar 14, 2025	39.24	-0.02	-0.05%	39.26	39.96	38.95
Mar 13, 2025	39.20	-0.79	-1.98%	39.99	40.39	39.13
Mar 12, 2025	40.20	1.92	5.02%	38.28	40.36	38.28
Mar 11, 2025	38.27	1.03	2.77%	37.24	38.51	37.16
Mar 10, 2025	37.43	-0.54	-1.42%	37.97	38.57	37.01
Mar 7, 2025	38.57	-0.99	-2.50%	39.56	40.16	38.56
Mar 6, 2025	39.96	0.46	1.16%	39.50	40.86	39.46
Mar 5, 2025	40.80	0.26	0.64%	40.54	41.31	39.57
Mar 4, 2025	41.02	0.76	1.89%	40.26	41.18	39.68

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

Leverage

2:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Ultragenyx Company profile

About Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company, which is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. The Company’s therapies and clinical-stage pipeline consist of four product categories, such as biologics, small molecules, gene therapy, and nucleic acid product candidates. The Company’s four approved product candidates include Crysvita (burosumab) is for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO); Mepsevii (vestronidase alfa) is for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome; Dojolvi (triheptanoin) is for the treatment of long-chain fatty acid oxidation disorders or LC-FAOD, and Evkeeza (evinacumab) is for the treatment of homozygous familial hypercholesterolemia (HoFH). The Company' clinical product candidates include DTX401, DTX301, UX143, GTX-102, UX701 and UX053.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Ultragenyx Pharmaceutical Inc revenues increased 30% to $351.4M. Net loss increased from $186.6M to $454M. Revenues reflect Crysvita collaboration revenue in profit-share territory segment increase of 33% to $171.2M, Dojolvi segment increase from $13M to $39.6M, United States segment increase of 27% to $301.1M, others segment increase of 96% to $23.6M.